NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.95 -0.60 (-3.63 %)
(As of 05/27/2018 03:57 AM ET)
Previous Close$15.95
Today's Range$15.75 - $16.60
52-Week Range$4.45 - $19.90
Volume377,302 shs
Average Volume578,724 shs
Market Capitalization$1.48 billion
P/E Ratio-11.31
Dividend YieldN/A
Beta5.94

About Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics logoIovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120

Debt

Debt-to-Equity RatioN/A
Current Ratio20.61
Quick Ratio20.61

Price-To-Earnings

Trailing P/E Ratio-11.31
Forward P/E Ratio-12.56
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.26 per share
Price / Book4.89

Profitability

EPS (Most Recent Fiscal Year)($1.41)
Net Income$-92,060,000.00
Net MarginsN/A
Return on Equity-53.45%
Return on Assets-50.55%

Miscellaneous

Employees63
Outstanding Shares89,640,000

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics (NASDAQ:IOVA) released its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.03. View Iovance Biotherapeutics' Earnings History.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Iovance Biotherapeutics.

What price target have analysts set for IOVA?

8 brokerages have issued 12-month target prices for Iovance Biotherapeutics' shares. Their forecasts range from $17.50 to $31.00. On average, they expect Iovance Biotherapeutics' stock price to reach $22.3571 in the next year. View Analyst Ratings for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/20/2018)
  • 2. Cowen Inc analysts commented, "IOVA reported that the first patient in LN-145’s Phase II cervical cancer study has been." (8/16/2017)
  • 3. HC Wainwright analysts commented, "We project that one or more of these patients who achieved early PRs could transform to CRs with more follow up time as the infused TILs continue to act." (6/7/2017)

Who are some of Iovance Biotherapeutics' key competitors?

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the folowing people:
  • Dr. Maria Fardis, CEO, Pres & Director (Age 50)
  • Dr. Michael T. Lotze M.D., Chief Scientific Officer and VP of R&D (Age 66)
  • Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 61)
  • Mr. Timothy E. Morris, CFO & Principal Accounting Officer (Age 56)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel

Has Iovance Biotherapeutics been receiving favorable news coverage?

News coverage about IOVA stock has trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Iovance Biotherapeutics earned a daily sentiment score of 0.24 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 47.10 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (9.01%), BlackRock Inc. (6.45%), Franklin Resources Inc. (5.93%), Farallon Capital Management LLC (4.63%), Victory Capital Management Inc. (2.55%) and Northern Trust Corp (0.97%). View Institutional Ownership Trends for Iovance Biotherapeutics.

Which major investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Prosight Management LP, Millennium Management LLC, Citigroup Inc., Barclays PLC, Balter Liquid Alternatives LLC, Allianz Asset Management GmbH and Allianz Asset Management GmbH. View Insider Buying and Selling for Iovance Biotherapeutics.

Which major investors are buying Iovance Biotherapeutics stock?

IOVA stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Farallon Capital Management LLC, BlackRock Inc., Artal Group S.A., Franklin Resources Inc., PointState Capital LP, Victory Capital Management Inc. and Northern Trust Corp. View Insider Buying and Selling for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $15.95.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $1.48 billion. The biotechnology company earns $-92,060,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Iovance Biotherapeutics employs 63 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]


MarketBeat Community Rating for Iovance Biotherapeutics (IOVA)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  406
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Iovance Biotherapeutics (NASDAQ:IOVA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Iovance Biotherapeutics in the last 12 months. Their average twelve-month price target is $22.3571, suggesting that the stock has a possible upside of 40.17%. The high price target for IOVA is $31.00 and the low price target for IOVA is $17.50. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.903.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.3571$20.9375$19.7778$15.3125
Price Target Upside: 40.17% upside44.90% upside6.91% upside90.22% upside

Iovance Biotherapeutics (NASDAQ:IOVA) Consensus Price Target History

Price Target History for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018B. RileyBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.00LowView Rating Details
5/11/2018HC WainwrightReiterated RatingBuy$22.00HighView Rating Details
2/9/2018Jefferies GroupBoost Price TargetBuy$31.00LowView Rating Details
1/31/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$13.00 ➝ $19.00LowView Rating Details
1/29/2018Wells Fargo & CoReiterated RatingBuy$23.00MediumView Rating Details
1/22/2018Chardan CapitalReiterated RatingBuyHighView Rating Details
10/25/2017FBR & CoReiterated RatingBuy$17.50N/AView Rating Details
8/16/2017CowenReiterated RatingBuyMediumView Rating Details
5/10/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$13.00LowView Rating Details
3/8/2017Roth CapitalSet Price TargetBuy$14.00LowView Rating Details
6/6/2016SunTrust BanksDowngradeBuy ➝ Neutral$37.00 ➝ $30.50N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Iovance Biotherapeutics (NASDAQ:IOVA) Earnings History and Estimates Chart

Earnings by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ:IOVA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.32)
2019 EPS Consensus Estimate: ($1.51)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.34)($0.30)($0.33)
Q2 20184($0.34)($0.30)($0.33)
Q3 20184($0.34)($0.31)($0.33)
Q4 20184($0.35)($0.31)($0.34)
Q1 20191($0.37)($0.37)($0.37)
Q2 20191($0.38)($0.38)($0.38)
Q3 20191($0.39)($0.39)($0.39)
Q4 20191($0.37)($0.37)($0.37)

Iovance Biotherapeutics (NASDAQ IOVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018($0.32)N/AView Earnings Details
5/10/2018Q1 2018($0.2880)($0.3140)ViewN/AView Earnings Details
3/12/2018Q4 2017($0.3220)($0.36)ViewListenView Earnings Details
10/31/2017Q3 2017($0.34)($0.35)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.35)($0.37)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.28)($0.33)ViewListenView Earnings Details
3/7/2017Q4 2016($0.25)($0.25)ViewListenView Earnings Details
11/4/2016Q316($0.22)($0.32)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.19)($0.23)ViewN/AView Earnings Details
5/9/2016Q1 2016($0.16)($0.14)ViewN/AView Earnings Details
3/10/2016Q4($0.20)($0.20)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.20)($0.16)ViewN/AView Earnings Details
8/10/2015Q2 2015($0.17)($0.14)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.11)($0.14)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Iovance Biotherapeutics (NASDAQ:IOVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Iovance Biotherapeutics (NASDAQ IOVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.90%
Institutional Ownership Percentage: 86.55%
Insider Trading History for Iovance Biotherapeutics (NASDAQ:IOVA)
Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

Iovance Biotherapeutics (NASDAQ IOVA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2016Sanford HillsbergDirectorSell54,000$8.95$483,300.00View SEC Filing  
8/22/2016Sanford HillsbergDirectorSell54,000$9.11$491,940.00View SEC Filing  
9/8/2015Sanford HillsbergDirectorSell32,500$6.99$227,175.00View SEC Filing  
5/6/2015Sanford HillsbergDirectorSell50,000$10.00$500,000.00View SEC Filing  
11/5/2013Manish SinghCEOBuy125,000$2.00$250,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Iovance Biotherapeutics (NASDAQ IOVA) News Headlines

Source:
DateHeadline
T-Cell Immunotherapy Market Projected to Grow at an Annualized Rate of 86%, Predicts Roots AnalysisT-Cell Immunotherapy Market Projected to Grow at an Annualized Rate of 86%, Predicts Roots Analysis
www.businesswire.com - May 23 at 8:49 AM
Iovance Biotherapeutics (IOVA) Lifted to Buy at BidaskClubIovance Biotherapeutics (IOVA) Lifted to Buy at BidaskClub
www.americanbankingnews.com - May 19 at 11:03 AM
4 Small Speculative Names on My Radar4 Small Speculative Names on My Radar
finance.yahoo.com - May 16 at 4:47 PM
Iovance Biotherapeutics (IOVA) Posts Quarterly  Earnings Results, Misses Expectations By $0.02 EPSIovance Biotherapeutics (IOVA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - May 12 at 12:28 AM
Iovance Biotherapeutics (IOVA) Lowered to "Hold" at BidaskClubIovance Biotherapeutics (IOVA) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - May 11 at 8:05 PM
HC Wainwright Reaffirms Buy Rating for Iovance Biotherapeutics (IOVA)HC Wainwright Reaffirms Buy Rating for Iovance Biotherapeutics (IOVA)
www.americanbankingnews.com - May 11 at 5:49 PM
Iovance Biotherapeutics (IOVA) PT Raised to $24.00 at B. RileyIovance Biotherapeutics (IOVA) PT Raised to $24.00 at B. Riley
www.americanbankingnews.com - May 11 at 5:43 PM
Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 1cIovance Biotherapeutics (IOVA) Misses Q1 EPS by 1c
www.streetinsider.com - May 11 at 10:13 AM
Iovance Biotherapeutics (IOVA) CEO Dr. Maria Fardis on Q1 2018 Results - Earnings Call TranscriptIovance Biotherapeutics' (IOVA) CEO Dr. Maria Fardis on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:13 AM
Iovance Biotherapeutics: 1Q Earnings SnapshotIovance Biotherapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 10:13 AM
Zacks: Analysts Anticipate Iovance Biotherapeutics (IOVA) Will Post Earnings of -$0.29 Per ShareZacks: Analysts Anticipate Iovance Biotherapeutics (IOVA) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - May 10 at 7:22 PM
Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate UpdateIovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 4:43 PM
Iovance Biotherapeutics (IOVA) Receives Average Rating of "Buy" from BrokeragesIovance Biotherapeutics (IOVA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 7 at 5:40 AM
New HQ puts Tampa immunotherapy company in Moffitts backyardNew HQ puts Tampa immunotherapy company in Moffitt's backyard
www.bizjournals.com - May 5 at 4:44 PM
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May ...Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May ...
globenewswire.com - May 5 at 4:44 PM
Iovance Biotherapeutics (IOVA) Raised to Strong-Buy at ValuEngineIovance Biotherapeutics (IOVA) Raised to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 4 at 12:17 AM
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast onIovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on
www.nasdaq.com - May 3 at 9:08 AM
New HQ puts Tampa immunotherapy company in Moffitt’s backyardNew HQ puts Tampa immunotherapy company in Moffitt’s backyard
finance.yahoo.com - May 3 at 9:08 AM
Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018
finance.yahoo.com - May 3 at 9:08 AM
Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in MayIovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May
finance.yahoo.com - May 2 at 9:04 AM
Critical Survey: Iovance Biotherapeutics (IOVA) & Its CompetitorsCritical Survey: Iovance Biotherapeutics (IOVA) & Its Competitors
www.americanbankingnews.com - April 30 at 5:21 AM
Iovance Biotherapeutics (IOVA) versus The Competition Head-To-Head ReviewIovance Biotherapeutics (IOVA) versus The Competition Head-To-Head Review
www.americanbankingnews.com - April 28 at 9:16 PM
Financial Contrast: Iovance Biotherapeutics (IOVA) & Its CompetitorsFinancial Contrast: Iovance Biotherapeutics (IOVA) & Its Competitors
www.americanbankingnews.com - April 27 at 3:32 AM
-$0.29 Earnings Per Share Expected for Iovance Biotherapeutics Inc (IOVA) This Quarter-$0.29 Earnings Per Share Expected for Iovance Biotherapeutics Inc (IOVA) This Quarter
www.americanbankingnews.com - April 23 at 11:20 AM
Iovance Biotherapeutics Inc (IOVA) Receives Consensus Rating of "Buy" from AnalystsIovance Biotherapeutics Inc (IOVA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 5:35 AM
Iovance Biotherapeutics (IOVA) Lifted to "Buy" at B. RileyIovance Biotherapeutics (IOVA) Lifted to "Buy" at B. Riley
www.americanbankingnews.com - April 10 at 8:37 AM
Jefferies Group Reiterates Buy Rating for Iovance Biotherapeutics (IOVA)Jefferies Group Reiterates Buy Rating for Iovance Biotherapeutics (IOVA)
www.americanbankingnews.com - April 9 at 1:27 PM
Iovance Biotherapeutics (IOVA) Upgraded at Zacks Investment ResearchIovance Biotherapeutics (IOVA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 11:38 AM
Iovance Biotherapeutics Inc (IOVA) Expected to Post Earnings of -$0.29 Per ShareIovance Biotherapeutics Inc (IOVA) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 6 at 11:29 AM
Iovance Biotherapeutics (IOVA) "Buy" Rating Reiterated at FBR & CoIovance Biotherapeutics' (IOVA) "Buy" Rating Reiterated at FBR & Co
www.americanbankingnews.com - April 5 at 2:25 PM
Iovance Biotherapeutics (IOVA) Downgraded by BidaskClub to "Buy"Iovance Biotherapeutics (IOVA) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 5 at 12:30 AM
Iovance Biotherapeutics (IOVA) Given a $16.00 Price Target at HC WainwrightIovance Biotherapeutics (IOVA) Given a $16.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 4 at 2:26 PM
Iovance Biotherapeutics (IOVA) Lifted to "Buy" at ValuEngineIovance Biotherapeutics (IOVA) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 1:22 PM
Iovance Biotherapeutics (IOVA) PT Set at $13.00 by OppenheimerIovance Biotherapeutics (IOVA) PT Set at $13.00 by Oppenheimer
www.americanbankingnews.com - April 2 at 3:42 PM
Iovance Biotherapeutics (IOVA) PT Raised to $18.00Iovance Biotherapeutics (IOVA) PT Raised to $18.00
www.americanbankingnews.com - April 2 at 3:15 PM
Contrasting Iovance Biotherapeutics (IOVA) and The CompetitionContrasting Iovance Biotherapeutics (IOVA) and The Competition
www.americanbankingnews.com - April 1 at 7:22 AM
Iovance Biotherapeutics (IOVA) Rating Increased to Buy at Zacks Investment ResearchIovance Biotherapeutics (IOVA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:42 PM
Zacks Investment Research Downgrades Iovance Biotherapeutics (IOVA) to HoldZacks Investment Research Downgrades Iovance Biotherapeutics (IOVA) to Hold
www.americanbankingnews.com - March 30 at 8:24 PM
Iovance Biotherapeutics (IOVA) Stock Rating Upgraded by BidaskClubIovance Biotherapeutics (IOVA) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 27 at 4:34 PM
Iovance Biotherapeutics (IOVA) Upgraded by ValuEngine to HoldIovance Biotherapeutics (IOVA) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - March 25 at 4:48 PM
Iovance Biotherapeutics (IOVA) Given a $22.00 Price Target by HC Wainwright AnalystsIovance Biotherapeutics (IOVA) Given a $22.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 18 at 10:24 AM
Iovance Biotherapeutics Inc (IOVA) Receives Average Rating of "Buy" from AnalystsIovance Biotherapeutics Inc (IOVA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 18 at 7:28 AM
Iovance Biotherapeutics (IOVA) Lowered to "Buy" at BidaskClubIovance Biotherapeutics (IOVA) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - March 16 at 11:34 PM
B. Riley Brokers Boost Earnings Estimates for Iovance Biotherapeutics Inc (IOVA)B. Riley Brokers Boost Earnings Estimates for Iovance Biotherapeutics Inc (IOVA)
www.americanbankingnews.com - March 15 at 9:22 AM
Iovance Biotherapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($0.31) Per Share (IOVA)Iovance Biotherapeutics Inc Forecasted to Earn Q3 2018 Earnings of ($0.31) Per Share (IOVA)
www.americanbankingnews.com - March 15 at 8:15 AM
Oppenheimer Comments on Iovance Biotherapeutics Incs Q1 2018 Earnings (IOVA)Oppenheimer Comments on Iovance Biotherapeutics Inc's Q1 2018 Earnings (IOVA)
www.americanbankingnews.com - March 15 at 7:57 AM
Analysts Offer Predictions for Iovance Biotherapeutics Incs Q1 2018 Earnings (IOVA)Analysts Offer Predictions for Iovance Biotherapeutics Inc's Q1 2018 Earnings (IOVA)
www.americanbankingnews.com - March 14 at 7:20 AM
Iovance Biotherapeutics (IOVA) Price Target Raised to $22.00Iovance Biotherapeutics (IOVA) Price Target Raised to $22.00
www.americanbankingnews.com - March 13 at 1:38 PM
Iovance Biotherapeutics (IOVA) Announces Quarterly  Earnings Results, Misses Estimates By $0.04 EPSIovance Biotherapeutics (IOVA) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - March 13 at 10:39 AM
Iovance Biotherapeutics posts 4Q lossIovance Biotherapeutics posts 4Q loss
finance.yahoo.com - March 12 at 4:44 PM

SEC Filings

Iovance Biotherapeutics (NASDAQ:IOVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Iovance Biotherapeutics (NASDAQ:IOVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Iovance Biotherapeutics (NASDAQ IOVA) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.